JP2022173554A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022173554A5 JP2022173554A5 JP2022160357A JP2022160357A JP2022173554A5 JP 2022173554 A5 JP2022173554 A5 JP 2022173554A5 JP 2022160357 A JP2022160357 A JP 2022160357A JP 2022160357 A JP2022160357 A JP 2022160357A JP 2022173554 A5 JP2022173554 A5 JP 2022173554A5
- Authority
- JP
- Japan
- Prior art keywords
- strand
- nucleic acid
- positions
- modified
- nucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020004707 nucleic acids Proteins 0.000 claims 27
- 150000007523 nucleic acids Chemical class 0.000 claims 27
- 102000039446 nucleic acids Human genes 0.000 claims 27
- 125000003729 nucleotide group Chemical group 0.000 claims 25
- 239000002773 nucleotide Substances 0.000 claims 24
- 230000004048 modification Effects 0.000 claims 11
- 238000012986 modification Methods 0.000 claims 11
- 125000001153 fluoro group Chemical group F* 0.000 claims 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 3
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 150000001720 carbohydrates Chemical class 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 2
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical group CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims 1
- -1 alkylene ether Chemical group 0.000 claims 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024121088A JP7823127B2 (ja) | 2017-04-05 | 2024-07-26 | 産物及び組成物 |
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17165129 | 2017-04-05 | ||
| EP17165129.2 | 2017-04-05 | ||
| GBGB1707203.4A GB201707203D0 (en) | 2017-05-05 | 2017-05-05 | Modified positions |
| GB1707203.4 | 2017-05-05 | ||
| GB1708397.3 | 2017-05-25 | ||
| GBGB1708397.3A GB201708397D0 (en) | 2017-05-25 | 2017-05-25 | Modified positions |
| EP17201352 | 2017-11-13 | ||
| EP17201352.6 | 2017-11-13 | ||
| PCT/EP2018/058766 WO2018185241A1 (en) | 2017-04-05 | 2018-04-05 | Products and compositions |
| JP2020504436A JP7155239B2 (ja) | 2017-04-05 | 2018-04-05 | 産物及び組成物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020504436A Division JP7155239B2 (ja) | 2017-04-05 | 2018-04-05 | 産物及び組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024121088A Division JP7823127B2 (ja) | 2017-04-05 | 2024-07-26 | 産物及び組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022173554A JP2022173554A (ja) | 2022-11-18 |
| JP2022173554A5 true JP2022173554A5 (OSRAM) | 2022-12-06 |
| JP7583005B2 JP7583005B2 (ja) | 2024-11-13 |
Family
ID=61899311
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020504436A Active JP7155239B2 (ja) | 2017-04-05 | 2018-04-05 | 産物及び組成物 |
| JP2022160357A Active JP7583005B2 (ja) | 2017-04-05 | 2022-10-04 | 産物及び組成物 |
| JP2024121088A Active JP7823127B2 (ja) | 2017-04-05 | 2024-07-26 | 産物及び組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020504436A Active JP7155239B2 (ja) | 2017-04-05 | 2018-04-05 | 産物及び組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024121088A Active JP7823127B2 (ja) | 2017-04-05 | 2024-07-26 | 産物及び組成物 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11015198B2 (OSRAM) |
| EP (2) | EP3607069B1 (OSRAM) |
| JP (3) | JP7155239B2 (OSRAM) |
| CN (1) | CN110520531A (OSRAM) |
| AU (1) | AU2018247925B2 (OSRAM) |
| DK (1) | DK3607069T3 (OSRAM) |
| ES (1) | ES2932831T3 (OSRAM) |
| FI (1) | FI3607069T3 (OSRAM) |
| HR (1) | HRP20221400T1 (OSRAM) |
| HU (1) | HUE061247T2 (OSRAM) |
| IL (2) | IL268828B2 (OSRAM) |
| LT (1) | LT3607069T (OSRAM) |
| PL (1) | PL3607069T3 (OSRAM) |
| RS (1) | RS63836B1 (OSRAM) |
| SI (1) | SI3607069T1 (OSRAM) |
| WO (1) | WO2018185241A1 (OSRAM) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016161388A1 (en) | 2015-04-03 | 2016-10-06 | University Of Massachusetts | Fully stabilized asymmetric sirna |
| WO2017030973A1 (en) | 2015-08-14 | 2017-02-23 | University Of Massachusetts | Bioactive conjugates for oligonucleotide delivery |
| US10478503B2 (en) | 2016-01-31 | 2019-11-19 | University Of Massachusetts | Branched oligonucleotides |
| US11753638B2 (en) | 2016-08-12 | 2023-09-12 | University Of Massachusetts | Conjugated oligonucleotides |
| RS63836B1 (sr) * | 2017-04-05 | 2023-01-31 | Silence Therapeutics Gmbh | Proizvodi i sastavi |
| JP7247167B2 (ja) * | 2017-04-05 | 2023-03-28 | サイレンス・セラピューティクス・ゲーエムベーハー | 産物及び組成物 |
| EP3483269A1 (en) * | 2017-11-13 | 2019-05-15 | Silence Therapeutics GmbH | Products and compositions |
| IL269517B2 (en) | 2017-04-05 | 2025-01-01 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of a target gene in a cell, conjugates thereof, compositions containing them, and medical uses thereof |
| CA3064590A1 (en) | 2017-06-23 | 2018-12-27 | University Of Massachusetts | Two-tailed self-delivering sirna and related methods |
| WO2019006455A1 (en) | 2017-06-30 | 2019-01-03 | Solstice Biologics, Ltd. | AUXILIARIES OF CHIRAL PHOSPHORAMIDITIS AND METHODS OF USE THEREOF |
| CA3081905C (en) | 2017-11-13 | 2023-10-03 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of lpa in a cell |
| CN110997919B (zh) * | 2017-12-01 | 2024-04-02 | 苏州瑞博生物技术股份有限公司 | 双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途 |
| WO2019143621A1 (en) | 2018-01-16 | 2019-07-25 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting aldh2 expression |
| EP3598995A1 (en) * | 2018-07-26 | 2020-01-29 | Silence Therapeutics GmbH | Products and compositions |
| JP7627042B2 (ja) * | 2018-08-23 | 2025-02-05 | ユニバーシティー オブ マサチューセッツ | Ｏ－メチルリッチ完全安定化オリゴヌクレオチド |
| PH12021550801B1 (en) | 2018-11-13 | 2024-04-26 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of lpa in a cell |
| CN113557023A (zh) * | 2019-01-16 | 2021-10-26 | 建新公司 | Serpinc1 iRNA组合物及其使用方法 |
| WO2020150636A1 (en) | 2019-01-18 | 2020-07-23 | University Of Massachusetts | Dynamic pharmacokinetic-modifying anchors |
| WO2020206350A1 (en) * | 2019-04-04 | 2020-10-08 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting gene expression in the central nervous system |
| CA3149835A1 (en) | 2019-08-09 | 2021-02-18 | University Of Massachusetts | Chemically modified oligonucleotides targeting snps |
| WO2021041247A1 (en) * | 2019-08-23 | 2021-03-04 | University Of Massachusetts | O-methyl rich fully stabilized oligonucleotides |
| US12365894B2 (en) | 2019-09-16 | 2025-07-22 | University Of Massachusetts | Branched lipid conjugates of siRNA for specific tissue delivery |
| WO2021081420A2 (en) * | 2019-10-24 | 2021-04-29 | Genevant Sciences Gmbh | Conjugates and methods for treating acromegaly |
| GEP20257742B (en) | 2020-03-06 | 2025-03-10 | Aligos Therapeutics Inc | Modified short interfering nucleic acid (sina) molecules and uses thereof |
| EP4157289A4 (en) | 2020-05-26 | 2024-06-26 | University Of Massachusetts | Synthetic oligonucleotides having regions of block and cluster modifications |
| EP4213882A4 (en) | 2020-09-15 | 2025-02-26 | Verve Therapeutics, Inc. | LIPID FORMULATIONS FOR GENE EDITING |
| JP2023547512A (ja) | 2020-11-04 | 2023-11-10 | ウニベルジテート ベルン | 細胞におけるｐｒｏｓ１の発現を阻害するための核酸 |
| EP4281085A4 (en) * | 2021-01-22 | 2025-12-24 | Alnylam Pharmaceuticals Inc | MODIFIED DOUBLE-STRANDED OLIGONUCLEOTIDES |
| WO2022184852A1 (en) * | 2021-03-03 | 2022-09-09 | Silence Therapeutics Gmbh | Conjugated nucleic acids comprising a phosphorodithioate for inhibiting gene expression in a cell |
| JP2024511473A (ja) * | 2021-03-24 | 2024-03-13 | アタランタ セラピューティクス，インコーポレーテッド | パターン化化学修飾を有する二本鎖ｓｉｒｎａ |
| AR126207A1 (es) | 2021-06-23 | 2023-09-27 | Univ Massachusetts | Compuestos de oligonucleotidos anti-flt1 optimizados para el tratamiento de la preeclampsia y otros desordenes angiogénicos |
| WO2023088227A1 (zh) | 2021-11-16 | 2023-05-25 | 上海舶望制药有限公司 | 抑制血管紧张素原(agt)蛋白表达的组合物和方法 |
| IL315546A (en) | 2022-03-16 | 2024-11-01 | Empirico Inc | GALNAC compositions to improve siRNA bioavailability |
| US12258563B2 (en) | 2022-03-28 | 2025-03-25 | Empirico Inc. | Modified oligonucleotides |
| WO2024200512A1 (en) | 2023-03-27 | 2024-10-03 | Silence Therapeutics Gmbh | Compounds and compositions for use in stem cell transplantation |
| WO2024245151A1 (zh) * | 2023-05-26 | 2024-12-05 | 维亚臻生物技术（苏州）有限公司 | 一种用于代谢疾病的双链核苷酸化合物及其应用 |
| AU2024321098A1 (en) * | 2023-08-09 | 2026-03-19 | Beijing Foyou Pharma Co., Ltd | Sirna for inhibiting dgat2 gene expression, sirna conjugate or prodrug and pharmaceutical composition thereof, and use thereof |
| US12553050B2 (en) | 2024-03-22 | 2026-02-17 | Takeda Pharmaceutical Company Limited | Compositions and methods for inhibiting cytochrome P450 family 7 subfamily a member 1 (CYP7A1) expression |
| CN118460651B (zh) * | 2024-07-10 | 2025-03-18 | 凯莱英医药集团（天津）股份有限公司 | 制备Cemdisiran的方法 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL9201440A (nl) | 1992-08-11 | 1994-03-01 | Univ Leiden | Triantennaire clusterglycosiden, hun bereiding en toepassing. |
| US7667030B2 (en) | 2002-02-20 | 2010-02-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA) |
| US9150605B2 (en) | 2002-11-05 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
| EP1931781B1 (en) | 2005-08-17 | 2016-07-27 | Sirna Therapeutics, Inc. | Chemically modified short interfering nucleic acid molecules that mediate rna interference |
| US20090306178A1 (en) * | 2006-03-27 | 2009-12-10 | Balkrishen Bhat | Conjugated double strand compositions for use in gene modulation |
| WO2009002944A1 (en) * | 2007-06-22 | 2008-12-31 | Isis Pharmaceuticals, Inc. | Double strand compositions comprising differentially modified strands for use in gene modulation |
| CN102006890A (zh) | 2007-12-04 | 2011-04-06 | 阿尔尼拉姆医药品有限公司 | 靶向脂质 |
| BRPI0907008A2 (pt) | 2008-01-31 | 2015-07-07 | Alnylam Pharmaceuticals Inc | Métodos otimizados para liberação de dsrna alvejando o gene pcsk9 |
| EP2247729B1 (en) | 2008-02-11 | 2019-05-01 | Phio Pharmaceuticals Corp. | Modified rnai polynucleotides and uses thereof |
| EP2342616A2 (en) | 2008-09-23 | 2011-07-13 | Alnylam Pharmaceuticals Inc. | Chemical modifications of monomers and oligonucleotides with cycloaddition |
| US9493774B2 (en) * | 2009-01-05 | 2016-11-15 | Rxi Pharmaceuticals Corporation | Inhibition of PCSK9 through RNAi |
| CA2812046A1 (en) | 2010-09-15 | 2012-03-22 | Alnylam Pharmaceuticals, Inc. | Modified irna agents |
| WO2012094115A1 (en) | 2010-12-17 | 2012-07-12 | Arrowhead Research Corporation | Compositions and methods for inhibiting expression of flt3 genes |
| AU2012268619B2 (en) * | 2011-06-06 | 2017-08-17 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of isocitrate dehydrogenase (IDH1) gene expression |
| JP6165723B2 (ja) | 2011-06-30 | 2017-07-19 | アローヘッド ファーマシューティカルズ インコーポレイテッド | Ｂ型肝炎ウイルスの遺伝子発現を阻害するための組成物および方法 |
| MY167390A (en) | 2011-11-18 | 2018-08-16 | Alnylam Pharmaceuticals Inc | Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases |
| IL303831A (en) * | 2011-11-18 | 2023-08-01 | Alnylam Pharmaceuticals Inc | Adapted RNAI factors |
| US9133461B2 (en) | 2012-04-10 | 2015-09-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the ALAS1 gene |
| US9127274B2 (en) | 2012-04-26 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Serpinc1 iRNA compositions and methods of use thereof |
| KR102096014B1 (ko) * | 2012-12-05 | 2020-04-03 | 알닐람 파마슈티칼스 인코포레이티드 | PCSK9 iRNA 조성물 및 그 사용 방법 |
| CA2921162A1 (en) | 2013-05-01 | 2014-11-06 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
| EA201592225A1 (ru) * | 2013-05-22 | 2016-04-29 | Элнилэм Фармасьютикалз, Инк. | КОМПОЗИЦИИ НА ОСНОВЕ iRNA TMPRSS6 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| EP4039278A1 (en) | 2013-07-11 | 2022-08-10 | Alnylam Pharmaceuticals, Inc. | Oligonucleotide-ligand conjugates and process for their preparation |
| EP3151839A4 (en) | 2014-06-06 | 2018-02-28 | Ionis Pharmaceuticals, Inc. | Compositions and methods for enhanced intestinal absorption of conjugated oligomeric compounds |
| IL316808A (en) | 2014-08-20 | 2025-01-01 | Alnylam Pharmaceuticals Inc | Modified double-stranded RNA materials and their uses |
| WO2016085852A1 (en) * | 2014-11-24 | 2016-06-02 | Alnylam Pharmaceuticals, Inc. | Tmprss6 irna compositions and methods of use thereof |
| CA2979703A1 (en) | 2015-03-17 | 2016-09-22 | Arrowhead Pharmaceuticals, Inc. | Compositions and methods for inhibiting gene expression of factor xii |
| WO2016149020A1 (en) | 2015-03-17 | 2016-09-22 | Arrowhead Research Corporation | Rna interference agents |
| WO2016161388A1 (en) * | 2015-04-03 | 2016-10-06 | University Of Massachusetts | Fully stabilized asymmetric sirna |
| JP7009356B2 (ja) | 2015-04-03 | 2022-01-25 | ユニバーシティ・オブ・マサチューセッツ | ハンチンチンｍＲＮＡをターゲティングするオリゴヌクレオチド化合物 |
| KR20180038465A (ko) | 2015-08-07 | 2018-04-16 | 애로우헤드 파마슈티컬스 인코포레이티드 | Ｂ형 간염 바이러스 감염에 대한 ｒｎａｉ 치료법 |
| WO2017030973A1 (en) * | 2015-08-14 | 2017-02-23 | University Of Massachusetts | Bioactive conjugates for oligonucleotide delivery |
| JOP20160211B1 (ar) | 2015-10-01 | 2021-08-17 | Arrowhead Pharmaceuticals Inc | تراكيب وأساليب لتثبيط تعبير جيني للـ lpa |
| EP3228326A1 (en) * | 2016-04-05 | 2017-10-11 | Silence Therapeutics GmbH | Nucleic acid linked to a trivalent glycoconjugate |
| CA3023764A1 (en) | 2016-06-06 | 2017-12-14 | Arrowhead Pharmaceuticals, Inc. | 5'-cyclo-phosphonate modified nucleotides |
| JOP20190015A1 (ar) | 2016-08-04 | 2019-02-04 | Arrowhead Pharmaceuticals Inc | عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب |
| UY37565A (es) | 2017-01-10 | 2018-07-31 | Arrowhead Pharmaceuticals Inc | Agentes de iarn alfa-1 antitripsina (aat), composiciones que incluyen agentes de iarn aat y métodos de uso |
| EP3573623B1 (en) | 2017-01-30 | 2026-03-04 | Arrowhead Pharmaceuticals, Inc. | Compositions and methods for inhibition of factor xii gene expression |
| RS63836B1 (sr) | 2017-04-05 | 2023-01-31 | Silence Therapeutics Gmbh | Proizvodi i sastavi |
| JP7247167B2 (ja) * | 2017-04-05 | 2023-03-28 | サイレンス・セラピューティクス・ゲーエムベーハー | 産物及び組成物 |
| TN2020000039A1 (en) | 2017-09-11 | 2021-10-04 | Arrowhead Pharmaceuticals Inc | Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3) |
| PE20201287A1 (es) | 2017-09-14 | 2020-11-24 | Arrowhead Pharmaceuticals Inc | Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de uso |
| CA3081905C (en) * | 2017-11-13 | 2023-10-03 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of lpa in a cell |
| CN110997919B (zh) | 2017-12-01 | 2024-04-02 | 苏州瑞博生物技术股份有限公司 | 双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途 |
| PH12021550801B1 (en) * | 2018-11-13 | 2024-04-26 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of lpa in a cell |
-
2018
- 2018-04-05 RS RS20221162A patent/RS63836B1/sr unknown
- 2018-04-05 ES ES18715706T patent/ES2932831T3/es active Active
- 2018-04-05 IL IL268828A patent/IL268828B2/en unknown
- 2018-04-05 HU HUE18715706A patent/HUE061247T2/hu unknown
- 2018-04-05 US US16/497,000 patent/US11015198B2/en active Active
- 2018-04-05 FI FIEP18715706.0T patent/FI3607069T3/fi active
- 2018-04-05 HR HRP20221400TT patent/HRP20221400T1/hr unknown
- 2018-04-05 EP EP18715706.0A patent/EP3607069B1/en active Active
- 2018-04-05 LT LTEPPCT/EP2018/058766T patent/LT3607069T/lt unknown
- 2018-04-05 EP EP22202294.9A patent/EP4219713A3/en active Pending
- 2018-04-05 IL IL321221A patent/IL321221A/en unknown
- 2018-04-05 PL PL18715706.0T patent/PL3607069T3/pl unknown
- 2018-04-05 WO PCT/EP2018/058766 patent/WO2018185241A1/en not_active Ceased
- 2018-04-05 JP JP2020504436A patent/JP7155239B2/ja active Active
- 2018-04-05 DK DK18715706.0T patent/DK3607069T3/da active
- 2018-04-05 SI SI201830836T patent/SI3607069T1/sl unknown
- 2018-04-05 AU AU2018247925A patent/AU2018247925B2/en active Active
- 2018-04-05 CN CN201880021538.7A patent/CN110520531A/zh active Pending
-
2021
- 2021-03-31 US US17/219,265 patent/US12084656B2/en active Active
-
2022
- 2022-10-04 JP JP2022160357A patent/JP7583005B2/ja active Active
-
2024
- 2024-07-26 JP JP2024121088A patent/JP7823127B2/ja active Active
- 2024-08-07 US US18/797,143 patent/US20250043288A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3607069T3 (fi) | Tuotteita ja koostumuksia | |
| ES2936863T3 (es) | Métodos para tratar infección por hepatitis B | |
| JP2019214587A5 (OSRAM) | ||
| JP2024081668A5 (OSRAM) | ||
| JP2023068035A5 (OSRAM) | ||
| JP2021526804A5 (OSRAM) | ||
| TW202540423A (zh) | 用於抑制17β-HSD第13型(HSD17B13)表現之RNAi藥劑、其組合物及使用方法 | |
| JP2024541962A5 (OSRAM) | ||
| JP2021521796A (ja) | 高コレステロール血症及び関連状態を治療するための、ｐｃｓｋ９を標的とするオリゴヌクレオチド | |
| JP2021500025A5 (OSRAM) | ||
| JP2018529732A5 (OSRAM) | ||
| BR112014014730B1 (pt) | estrutura de droga polímero terapêutica, métodos para preparar uma estrutura de oligo rna de dupla hélice, nanoparticula e composição farmacêutica | |
| JP2024539629A5 (OSRAM) | ||
| JP2023519246A5 (OSRAM) | ||
| CN111601891A (zh) | 用于抑制aldh2表达的组合物和方法 | |
| JP2022517742A5 (OSRAM) | ||
| KR20170120617A (ko) | 수포성 표피 박리증 치료를 위한 col7a1 엑손 73에 대응하는 올리고뉴클레오타이드 | |
| TW202140787A (zh) | 用於調節ｓｍｎ２之化合物及方法 | |
| JP2024514880A (ja) | Ｐｎｐｌａ３発現を調節するための組成物及び方法 | |
| JP2009531433A5 (OSRAM) | ||
| JP2005508885A5 (OSRAM) | ||
| CN118496291A (zh) | 经修饰的双链寡核苷酸及其用途 | |
| CN115702006A (zh) | 缀合基团及其缀合物 | |
| EP3677680A1 (en) | Small guide antisense nucleic acid and use thereof | |
| JP2003505517A (ja) | 接合体ならびにそれらの製造方法および生体膜を横切り分子を輸送するためのそれらの使用 |